Company Focus
CSL Limited.
Latest CSL Limited. News
Biotechnology
CSL Seqirus has entered into a pioneering long-term agreement with the Pan American Health Organization (PAHO) Regional Revolving Fund to advance influenza protection in the LATAM region. 13 March 2026
Related News
Insights
Company Spotlight
A biotechnology company, based in China, developing car-t-based therapeutics for haematological and metabolic and endocrine diseases with a focus on addressing unmet medical need.
Latest News & Features of interest to CSL Limited.
Biotechnology
Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX 011, a first in class, mutation agnostic antibody with potential to disrupt the $2 billion essential thrombocythemia (ET) market. 16 April 2026
Pharmaceutical
USA-based SQ Innovation has struck a long-term supply agreement with Italian active pharmaceutical ingredient (API) specialist FIS to secure pharmaceutical-grade furosemide for its marketed product Lasix ONYU and future pipeline assets. 16 April 2026
Pharmaceutical
German drugmaker Bayer has highlighted publication of full results from its Phase III OCEANIC-STROKE trial in the New England Journal of Medicine, adding weight to its case for the investigational anticoagulant asundexian. 16 April 2026
Pharmaceutical
New research from researchers at the University of Florida, University of Maryland and Yale School of Public Health has found that if measles, mumps and rubella (MMR) immunization rates continue to fall, even by just a percentage point, measles could re-establish itself as an endemic disease in the USA within years. 16 April 2026
Biotechnology
Enodia Therapeutics, a privately-held French biotech developing small molecule therapies targeting a unique form of protein degradation at the point of synthesis, has appointed Yvonne McGrath as chief scientific officer (CSO). 15 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has determined that only a clinical trial - rather than a nonclinical or observational study - will be sufficient to prove the safety of Eli Lilly’s new obesity drug, Foundayo (orforglipron). 15 April 2026
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-322 trial. 14 April 2026
Pharmaceutical
US biopharma Travere Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Filspari (sparsentan) to reduce proteinuria in adult and pediatric patients aged eight years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. 14 April 2026
Pharmaceutical
Novo Nordisk has announced a strategic partnership with OpenAI, the US AI research and deployment company. 14 April 2026
Latest In Brief for CSL Limited.
Pharmaceutical
KDventures has revealed that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of an application for continued listing of the combined entity. 25 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze